IMCR - Immunocore eye cancer drug receives applaud after Health Canada's approval

Immunocore (NASDAQ:IMCR) said on Friday that Ocumel Canada and Save Your Skin Foundation applauded Canada's approval of Kimmtrak to treat a type of rare cancer called uveal melanoma. Uveal melanoma is a type of cancer that begins in the cells that make the dark-colored pigment, called melanin, in the uvea or uveal tract of the eye. On Wednesday, the company received approval for its eye cancer drug in Australia, Canada and UK. "For years, metastatic uveal melanoma patients have had to make do with therapeutic options not ideally suited for their condition," said said Marcus Butler, Ocular Melanoma Physician Task Force of Canada co-Lead.

For further details see:

Immunocore eye cancer drug receives applaud after Health Canada's approval